Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

Por Rassi, Fuad El, Khoury, Hanna Jean
Publicado em 2013

Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate

Por Shen, Ann Q., Munteanu, Mihaela, Khoury, Hanna Jean
Publicado no Oncologist (2014)

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

Por Jain, Preetesh, Romo, Carlos Guillermo, Khoury, Hanna J., Kantarjian, Hagop, Cortes, Jorge
Publicado em 2013

Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview

Por Shen, Ann Q., Wilson, Nicole M., Gleason, Shannon L., Khoury, Hanna Jean
Publicado em 2014

A Large Stone Within a Ureteroceles: A Diagnostic Pitfall and the Utility of Holmium Laser Deroofing as a Viable Surgical Option

Por El-Khoury, Hanna Jamil, Aw, Hau Choong, Gilbourd, Daniel, Liu, Madalena Ian-Pim
Publicado no J Endourol Case Rep (2018)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

Por Lima, Lisa M, Arellano, Martha, Holloway, Stacie, Shepard, Marian, McMillan, Stephanie, Khoury, Hanna Jean
Publicado em 2010

Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529

Por Kang, Sumin, Dong, Shaozhong, Guo, Ailan, Ruan, Hong, Lonial, Sagar, Khoury, Hanna Jean, Gu, Ting-Lei, Chen, Jing
Publicado em 2007

SRPK2 Promotes Leukemia Cell Proliferation by Phosphorylating Acinus and Regulating Cyclin A1

Por Jang, Sung-Wuk, Yang, Seung-ju, Ehlén, Åsa, Dong, Shaozhong, Khoury, Hanna, Chen, Jing, Persson, Jenny L., Ye, Keqiang
Publicado em 2008

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells

Por Dong, Shaozhong, Kang, Sumin, Gu, Ting-Lei, Kardar, Sean, Fu, Haian, Lonial, Sagar, Khoury, Hanna Jean, Khuri, Fadlo, Chen, Jing
Publicado em 2007

Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation

Por Jillella, Anand P., Arellano, Martha L., Heffner, Leonard T., Gaddh, Manila, Langston, Amelia A., Khoury, Hanna J., Mangoankar, Abhishek, Kota, Vamsi K.
Publicado no Hematol Rep (2017)

ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation

Por Jillella, Anand P., Arellano, Martha L., Heffner, Leonard T., Gaddh, Manila, Langston, Amelia A., Khoury, Hanna J., Mangaonkar, Abhishek, Kota, Vamsi K.
Publicado no Hematol Rep (2019)

The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV AND HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac

Por Ramachandiran, Sampath, Cain, Joan, Liao, Albert, He, Yanjuan, Guo, Xiangxue, Boise, Lawrence H., Fu, Haian, Ratner, Lee, Khoury, Hanna Jean, Bernal-Mizrachi, Leon
Publicado em 2012

Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia

Por Munker, Reinhold, Brazauskas, Ruta, Wang, Hai Lin, de Lima, Marcos, Khoury, Hanna J., Gale, Robert Peter, Maziarz, Richard T, Sandmaier, Brenda M, Weisdorf, Daniel, Saber, Wael
Publicado no Biol Blood Marrow Transplant (2016)

p90RSK2 is essential for FLT3-ITD– but dispensable for BCR-ABL–induced myeloid leukemia

Por Elf, Shannon, Blevins, Dean, Jin, Lingtao, Chung, Tae-Wook, Williams, Ifor R., Lee, Benjamin H., Lin, Jian-Xin, Leonard, Warren J., Taunton, Jack, Khoury, Hanna J., Kang, Sumin
Publicado em 2011

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

Por Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Lipton, Jeff H., Kim, Dong‐Wook, Schafhausen, Philippe, Matczak, Ewa, Leip, Eric, Noonan, Kay, Brümmendorf, Tim H., Gambacorti‐Passerini, Carlo
Publicado no Am J Hematol (2016)

FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway

Por Kang, Sumin, Dong, Shaozhong, Gu, Ting-Lei, Guo, Ailan, Cohen, Michael S., Lonial, Sagar, Khoury, Hanna Jean, Fabbro, Doriano, Gary Gilliland, D., Leif Bergsagel, P., Taunton, Jack, Polakiewicz, Roberto D., Chen, Jing
Publicado em 2007

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Por Ottmann, Oliver, Saglio, Giuseppe, Apperley, Jane F., Arthur, Christopher, Bullorsky, Eduardo, Charbonnier, Aude, Dipersio, John F., Kantarjian, Hagop, Khoury, Hanna Jean, Kim, Dong-Wook, Healey, Diane, Strauss, Lewis, Cortes, Jorge E.
Publicado no Blood Cancer J (2018)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

Por Brümmendorf, Tim H., Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Kim, Dong‐Wook, Schafhausen, Philippe, Conlan, Maureen G., Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Gambacorti‐Passerini, Carlo, Lipton, Jeff H.
Publicado no Br J Haematol (2015)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

Por Gambacorti‐Passerini, Carlo, Kantarjian, Hagop M., Kim, Dong‐Wook, Khoury, Hanna J., Turkina, Anna G., Brümmendorf, Tim H., Matczak, Ewa, Bardy‐Bouxin, Nathalie, Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Cortes, Jorge E.
Publicado no Am J Hematol (2015)

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase ch...

Por Shah, Neil P., Kim, Dong-Wook, Kantarjian, Hagop, Rousselot, Philippe, Llacer, Pedro Enrique Dorlhiac, Enrico, Alicia, Vela-Ojeda, Jorge, Silver, Richard T., Khoury, Hanna Jean, Müller, Martin C., Lambert, Alexandre, Matloub, Yousif, Hochhaus, Andreas
Publicado em 2010